# Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients

> **NCT04632342** · PHASE2 · UNKNOWN · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 87 (estimated)

## Conditions studied

- Radiation Pneumonitis
- Lung Cancer

## Interventions

- **DRUG:** HL301 tablet 300mg
- **DRUG:** Placebo of HL301 tablet

## Key facts

- **NCT ID:** NCT04632342
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11
- **Primary completion:** 2022-01
- **Final completion:** 2022-02
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2020-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04632342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04632342, "Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04632342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*